Enveric Biosciences issued U.S. patent for tryptamine-derive prodrugs

Enveric Biosciences announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,707,447, titled “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder. This new patent, issued July 25, 2023, provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives. These enhancements to the tryptamine chemical structure are designed to potentially elicit a more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs, such as psilocybin. Enveric’s lead product candidate, EB-373, is a new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder.